Corticosteroid Guidance for Pregnancy during COVID-19 Pandemic. Am J Perinatol 2020 Jun;37(8):809-812
Date
04/11/2020Pubmed ID
32274772Pubmed Central ID
PMC7356057DOI
10.1055/s-0040-1709684Scopus ID
2-s2.0-85083865722 (requires institutional sign-in at Scopus site) 45 CitationsAbstract
The novel coronavirus disease 2019 (COVID-19) pandemic is causing a necessary, rapid adjustment within the field of obstetrics. Corticosteroid use is a mainstay of therapy for those women delivering prematurely. Unfortunately, corticosteroid use has been associated with worse outcomes in COVID-19 positive patients. Given this information, it is necessary that obstetricians adjust practice to carefully weigh the fetal benefits with maternal risks. Therefore, our institution has examined the risks and benefits and altered our corticosteroid recommendations. KEY POINTS: · Corticosteroid use is an important part of prematurity treatment because it provides benefit to the fetus.. · Corticosteroid use may be related with increased morbidity and mortality in novel coronavirus disease 2019 (COVID-19).. · Therefore, during the COVID-19 pandemic, an alteration in current corticosteroid practices is necessary to uniquely weigh the maternal risks and fetal benefits..
Author List
McIntosh JJAuthor
Jennifer Jury Mcintosh DO Associate Professor in the Obstetrics and Gynecology department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
BetacoronavirusBetamethasone
Coronavirus Infections
Dexamethasone
Female
Fetal Organ Maturity
Gestational Age
Glucocorticoids
Humans
Pandemics
Pneumonia, Viral
Pregnancy
Pregnancy Complications, Infectious
Premature Birth
Prenatal Care
Risk Assessment
